Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Chuanlong Guci Capsule is a Traditional Chinese Medicine (TCM) formulation developed and manufactured by Taiji Group Chongqing Tongjunge Pharmaceutical Factory. It is primarily indicated for the treatment of hyperostosis (bone spurs), cervical spondylosis, lumbar muscle strain, and osteoarthritis. The formulation is composed of several herbal extracts, including *Dioscorea nipponica* (Chuanlongshu), *Epimedium* (Yinyanghuo), *Rehmannia glutinosa* (Shudi), *Drynaria fortunei* (Gusuibu), *Cibotium barometz* (Gouji), *Achyranthes bidentata* (Niuxi), and *Pyrola calliantha* (Ludiicao). Traditionally, these ingredients are used to dispel wind-dampness, invigorate blood circulation, and strengthen the kidneys and bones. Pharmacologically, the capsule is recognized for its anti-inflammatory and analgesic properties, which help alleviate joint pain and improve mobility in patients with degenerative bone conditions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Chuanlong Guci Capsule.